La Famiglia

La Famiglia, founded in Berlin and now part of General Catalyst, sits at an unusual intersection: an early-stage technology fund with limited partners drawn from European industrial families, alongside the institutional scale of a global venture platform. That combination produces a distinctive proposition for B2B founders, particularly those selling into established enterprise buyers in healthcare, manufacturing, and finance.

The healthcare thesis is concentrated on AI/ML in healthcare and health IT software, with a bias toward enterprise B2B founders building products that touch real industrial or clinical workflows. The firm is most useful when the target buyer profile overlaps with the operating businesses inside its LP base, since warm introductions into mid-market and large European industrial groups remain genuinely scarce for early-stage health software founders. Specific healthcare portfolio companies are not enumerated in the source material, so founders should ask for relevant references during diligence.

La Famiglia invests at Pre-Seed, Seed, and Series A, with checks of one to five million dollars. The geographic focus is Europe, anchored in Germany and the broader DACH region, with selective activity beyond. For founders whose go-to-market depends on cracking conservative European enterprise buyers, the family-network access is the differentiated asset and the one founders should pressure-test in diligence by asking for specific introductions before signing rather than after.

The team is composed of partners with backgrounds in operating roles, family-office investing, and venture capital. Specific partner names are not provided in the source material, and founders should clarify partner ownership of the healthcare thesis early.

The right founders for La Famiglia are those building enterprise B2B health software where the bottleneck is access and trust with conservative buyers, not technical risk. The wrong founders are consumer-facing or US-anchored teams, where the family network is less directly useful. La Famiglia is also not a fit for highly clinically regulated programs that require deep healthcare-specialist operating support; the firm is comfortable with regulatory complexity but not built around it. Founders should arrive with a clear list of named target accounts and a credible explanation of why the LP network would shorten the sales cycle into them. The firm rewards specificity in commercial planning and tends to be impatient with founders who treat distribution as a generic problem to be solved later.